NLRP3-IN-12

NLRP3-IN-12

• UNSPSC Description: NLRP3-IN-12 is a specific NLRP3 inflammasome inhibitor. NLRP3-IN-12 reduces the release of IL-1β by targeting the NLRP3 protein, with an IC50 of 0.45 μM. NLRP3-IN-12 can be used for the research of inflammatory bowel disease[1].
• Target Antigen: NOD-like Receptor (NLR)
• Type: Reference compound
• Related Pathways: Immunology/Inflammation
• Applications: COVID-19-immunoregulation
• Field of Research: Inflammation/Immunology
• Assay Protocol: https://www.medchemexpress.com/nlrp3-in-12.html
• Solubility: 10 mM in DMSO
• Smiles: O[C@@H]1[C@]2(CO3)[C@@]([C@H](O)[C@]3(O)[C@]45[C@@]2([H])CC[C@](C(C5=O)=C)([H])[C@@]4([H])OC(NC6=CC=CC(Cl)=C6)=O)([H])C(C)(C)CC1
• Molecular Weight: 518.00
• References & Citations: [1]Pang L, et, al. Development of novel oridonin analogs as specifically targeted NLRP3 inflammasome inhibitors for the treatment of dextran sulfate sodium-induced colitis. Eur J Med Chem. 2023 Jan 5;245(Pt 2):114919.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported